BETA Technologies (NYSE:BETA – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both industrials companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.
Profitability
This table compares BETA Technologies and Mainz Biomed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BETA Technologies | -1,913.91% | -96.24% | -48.20% |
| Mainz Biomed | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for BETA Technologies and Mainz Biomed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BETA Technologies | 1 | 1 | 9 | 0 | 2.73 |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
Earnings & Valuation
This table compares BETA Technologies and Mainz Biomed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BETA Technologies | $35.62 million | 132.12 | -$745.87 million | ($13.02) | -1.60 |
| Mainz Biomed | $659,935.00 | 18.53 | -$21.65 million | ($65.60) | -0.02 |
Mainz Biomed has lower revenue, but higher earnings than BETA Technologies. BETA Technologies is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Summary
BETA Technologies beats Mainz Biomed on 6 of the 11 factors compared between the two stocks.
About BETA Technologies
BETA Technologies Inc. is an electric aerospace company. It involved in designing, manufacturing and selling high-performance electric aircraft, advanced electric propulsion systems, components and charging systems. BETA Technologies Inc. is based in SOUTH BURLINGTON.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Receive News & Ratings for BETA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BETA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
